IDEAS home Printed from https://ideas.repec.org/e/pgr189.html
   My authors  Follow this author

Paul Vincent Grootendorst

Personal Details

First Name:Paul
Middle Name:Vincent
Last Name:Grootendorst
Suffix:
RePEc Short-ID:pgr189
http://individual.utoronto.ca/grootendorst/

Affiliation

(80%) University of Toronto, Faculty of Pharmacy

http://www.pharmacy.utoronto.ca/
Canada, Toronto

(10%) Department of Economics
McMaster University

Hamilton, Canada
http://www.mcmaster.ca/economics/

: (905) 525-9140 ext. 22765
(905) 521-8232
1280 Main Street West, Hamilton, Ontario, L8S 4M4
RePEc:edi:demcmca (more details at EDIRC)

(10%) School of Public Policy and Governance
University of Toronto

Toronto, Canada
http://www.publicpolicy.utoronto.ca/

: 416 978 5120
416 978 5079
Canadiana Building, 3rd floor, 14 Queen's Park Cres. West, Toronto, ON M5S 3K9
RePEc:edi:spputca (more details at EDIRC)

Research output

as
Jump to: Working papers Articles Chapters

Working papers

  1. Paul Grootendorst & Minsup Shim & Adam Falconi & Tyler Robinson & Ethar Ismail & Joel Lexchin, 2015. "Intellectual Property Protection And Drug Plan Coverage: Evidence From Ontario," Working Papers 150005, Canadian Centre for Health Economics.
  2. Guy E.J. Faulkner & Paul Grootendorst & Van Hai Nguyen & Tatiana Andreyeva & Kelly Arbour-Nicitopoulos & Chris Auld & Sean B. Cash & John Cawley & Peter Donnelly & Adam Drewnowski & Laurette Dubé & Ro, 2011. "Economic Instruments for Obesity Prevention: Results of a Scoping Review and Modified Delphi Survey," Monash Economics Working Papers 31-11, Monash University, Department of Economics.
  3. Paul Grootendorst, 2009. "How should we support pharmaceutical innovation?," Social and Economic Dimensions of an Aging Population Research Papers 246, McMaster University.
  4. Paul Grootendorst, 2009. "Patents, Public-Private Partnerships or Prizes – How should we support pharmaceutical innovation?," Social and Economic Dimensions of an Aging Population Research Papers 250, McMaster University.
  5. Paul Grootendorst & Emmanuelle Piérard & Minsup Shim, 2007. "The life expectancy gains from pharmaceutical drugs: a critical appraisal of the literature," Social and Economic Dimensions of an Aging Population Research Papers 221, McMaster University.
  6. Paul Grootendorst, 2007. "A review of instrumental variables estimation in the applied health sciences," Social and Economic Dimensions of an Aging Population Research Papers 215, McMaster University.
  7. Paul Grootendorst, 2007. "Effects of 'Authorized-Generics' on Canadian Drug Prices," Social and Economic Dimensions of an Aging Population Research Papers 201, McMaster University.
  8. Paul V. Grootendorst & John K. Marshall & Anne M. Holbrook & Lisa R. Dolovich & Bernie J. O'Brien & Adrian R. Levy, 2004. "The Impact of Differential Cost Sharing of Non-Steroidal Anti-Inflammatory Agents on the Use and Costs of Analgesic Drugs," Social and Economic Dimensions of an Aging Population Research Papers 115, McMaster University.
  9. Thomas F. Crossley & Paul V. Grootendorst & Michael R. Veall, 2003. "National Catastrophic Drug Insurance Revisited: Who Would Benefit from Senator Kirby's Recommendations?," Social and Economic Dimensions of an Aging Population Research Papers 105, McMaster University.
  10. Alan, Sule & Crossley, Thomas F. & Grootendorst, Paul & Veall, Michael R., 2003. "Out-of-Pocket Prescription Drug Expenditures and Public Prescription Drug Programs," IZA Discussion Papers 695, Institute of Labor Economics (IZA).
  11. Paul V. Grootendorst & Mitchell Levine, 2002. "Do Drug Plans Matter? Effects of Drug Plan Eligibility on Drug Use Among the Elderly, Social Assistance Recipients and the General Population," Social and Economic Dimensions of an Aging Population Research Papers 73, McMaster University.
  12. Paul V. Grootendorst & Lisa R. Dolovich & Anne M. Holbrook & Adrian R. Levy & Bernie J. O'Brien, 2002. "The Impact of Reference Pricing of Cardiovascular Drugs on Health Care Costs and Health Outcomes: Evidence from British Columbia--Volume II: Technical Report," Social and Economic Dimensions of an Aging Population Research Papers 71, McMaster University.
  13. Paul V. Grootendorst & Lisa R. Dolovich & Anne M. Holbrook & Adrian R. Levy & Bernie J. O'Brien, 2002. "The Impact of Reference Pricing of Cardiovascular Drugs on Health Care Costs and Health Outcomes: Evidence from British Columbia--Volume I: Summary," Social and Economic Dimensions of an Aging Population Research Papers 70, McMaster University.
  14. Donald Willison & Mary Wiktorowicz & Paul Grootendorst & Bernie O'Brien & Mitchell Levine & Raisa Deber & Jeremiah Hurley, 2001. "International Experience With Pharmaceutical Policy: Common Challenges and Lessons for Canada," Centre for Health Economics and Policy Analysis Working Paper Series 2001-08, Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada.
  15. Thomas F. Crossley & Paul Grootendorst & Sule Korkmaz & Michael R. Veall, 2000. "The Effects of Drug Subsidies on Out-of Pocket Prescription Drug Expenditures by Seniors: Regional Evidence from Canada," Social and Economic Dimensions of an Aging Population Research Papers 19, McMaster University.
  16. P Grootendorst & D Feeny & W Furlong, 1999. "Health Utilities Index Mark 3: Evidence of Construct Validity for Stroke and Arthritis in a Population Health Survey," Centre for Health Economics and Policy Analysis Working Paper Series 1999-06, Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada.
  17. P Grootendorst, 1999. "Beneficiary Cost Sharing Under Canadian Provincial Prescription Drug Benefit Programs: History and Assessment," Centre for Health Economics and Policy Analysis Working Paper Series 1999-10, Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada.
  18. Paul Grootendorst & David Feeney & W. Furlong, 1999. "Evidence of Construct Validity for Stoke and Arthritis in a Population Health Survey," Department of Economics Working Papers 1999-09, McMaster University.
  19. Donald Willison & Paul Grootendorst & Jeremiah Hurley, 1998. "Variance in Pharmacare Coverage Across Canada," Centre for Health Economics and Policy Analysis Working Paper Series 1998-08, Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada.
  20. Paul Grootendorst & Laurie Goldsmith & Jeremiah Hurley & Bernie O'Brien & Lisa Dolovich, 1996. "Financial Incentives to Dispense Low-Cost Drugs: A Case Study of British Columbia Pharmacare," Centre for Health Economics and Policy Analysis Working Paper Series 1996-08, Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada.
  21. P Grootendorst & B O'Brien & G Anderson, 1995. "On Becoming 65 in Ontario: Effects of Provincial Drug Plan Eligibility on Utilization of Prescription Medicines," Centre for Health Economics and Policy Analysis Working Paper Series 1995-01, Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada.
  22. P Grootendorst & D Feeny & W Furlong, 1994. "Does It Matter Whom and How You Ask? Inter and Intra-rater Agreement in the Ontario Health Survey," Centre for Health Economics and Policy Analysis Working Paper Series 1994-12, Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada.
  23. Paul Grootendorst, 1993. "Results of an Investigation into the Integrity of the Ontario Health Survey," Centre for Health Economics and Policy Analysis Working Paper Series 1993-11, Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada.
  24. Christopher Auld & Paul Grootendorst, "undated". "An Empirical Analysis of Milk Addiction," Working Papers 2001-17, Department of Economics, University of Calgary, revised 05 Dec 2001.

Articles

  1. Emmanuelle Piérard & Paul Grootendorst, 2014. "Do downturns cause desperation? The effect of economic conditions on suicide rates in Canada," Applied Economics, Taylor & Francis Journals, vol. 46(10), pages 1081-1092, April.
  2. Morgan, Steve & Grootendorst, Paul & Lexchin, Joel & Cunningham, Colleen & Greyson, Devon, 2011. "The cost of drug development: A systematic review," Health Policy, Elsevier, vol. 100(1), pages 4-17, April.
  3. Marshall, Deborah A. & Willison, Donald J. & Grootendorst, Paul & LeLorier, Jacques & Maclure, Malcolm & Kulin, Nathalie A. & Sheehy, Odile E. & Warren, Leanne & Sykora, Kathy & Rahme, Elham, 2007. "The effects of coxib formulary restrictions on analgesic use and cost: Regional evidence from Canada," Health Policy, Elsevier, vol. 84(1), pages 1-13, November.
  4. Paul Grootendorst & David Stewart, 2006. "A re-examination of the impact of reference pricing on anti-hypertensive drug plan expenditures in British Columbia," Health Economics, John Wiley & Sons, Ltd., vol. 15(7), pages 735-742.
  5. Paul Contoyannis & Jeremiah Hurley & Paul Grootendorst & Sung-Hee Jeon & Robyn Tamblyn, 2005. "Estimating the price elasticity of expenditure for prescription drugs in the presence of non-linear price schedules: an illustration from Quebec, Canada," Health Economics, John Wiley & Sons, Ltd., vol. 14(9), pages 909-923.
  6. Paul V. Grootendorst & Michael R. Veall, 2005. "National Catastrophic Drug Insurance Revisited: Who Would Benefit from Senator Kirby's Recommendations?," Canadian Public Policy, University of Toronto Press, vol. 31(4), pages 341-358, December.
  7. Sule Alan & Thomas Crossley & Paul Grootendorst & Michael Veall, 2005. "Distributional effects of `general population' prescription drug programs in Canada," Canadian Journal of Economics, Canadian Economics Association, vol. 38(1), pages 128-148, February.
  8. Auld, M. Christopher & Grootendorst, Paul, 2004. "An empirical analysis of milk addiction," Journal of Health Economics, Elsevier, vol. 23(6), pages 1117-1133, November.
  9. Alan, Sule & Crossley, Thomas F. & Grootendorst, Paul & Veall, Michael R., 2002. "The effects of drug subsidies on out-of-pocket prescription drug expenditures by seniors: regional evidence from Canada," Journal of Health Economics, Elsevier, vol. 21(5), pages 805-826, September.
  10. Schneeweiss, Sebastian & Maclure, Malcolm & Walker, Alexander M. & Grootendorst, Paul & Soumerai, Stephen B., 2001. "On the evaluation of drug benefits policy changes with longitudinal claims data: the policy maker's versus the clinician's perspective," Health Policy, Elsevier, vol. 55(2), pages 97-109, February.
  11. Paul V. Grootendorst, 1997. "Health care policy evaluation using longitudinal insurance claims data: An application of the Panel Tobit estimator," Health Economics, John Wiley & Sons, Ltd., vol. 6(4), pages 365-382.

Chapters

  1. Paul Grootendorst, 2012. "Prescription Drug Insurance and Reimbursement," Chapters,in: The Elgar Companion to Health Economics, Second Edition, chapter 11 Edward Elgar Publishing.

Citations

Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.

Working papers

  1. Guy E.J. Faulkner & Paul Grootendorst & Van Hai Nguyen & Tatiana Andreyeva & Kelly Arbour-Nicitopoulos & Chris Auld & Sean B. Cash & John Cawley & Peter Donnelly & Adam Drewnowski & Laurette Dubé & Ro, 2011. "Economic Instruments for Obesity Prevention: Results of a Scoping Review and Modified Delphi Survey," Monash Economics Working Papers 31-11, Monash University, Department of Economics.

    Cited by:

    1. Just, David R. & Gabrielyan, Gnel, 2018. "Influencing the food choices of SNAP consumers: Lessons from economics, psychology and marketing," Food Policy, Elsevier, vol. 79(C), pages 309-317.

  2. Paul Grootendorst, 2009. "How should we support pharmaceutical innovation?," Social and Economic Dimensions of an Aging Population Research Papers 246, McMaster University.

    Cited by:

    1. Sonia Bhalotra & Atheendar Venkataramani, 2011. "The Captain of the Men of Death and His Shadow: Long-Run Impacts of Early Life Pneumonia Exposure," CHILD Working Papers wp20_11, CHILD - Centre for Household, Income, Labour and Demographic economics - ITALY.

  3. Paul Grootendorst & Emmanuelle Piérard & Minsup Shim, 2007. "The life expectancy gains from pharmaceutical drugs: a critical appraisal of the literature," Social and Economic Dimensions of an Aging Population Research Papers 221, McMaster University.

    Cited by:

    1. Vincenzo Atella & Francesco D'Amico, 2010. "Who is responsible for your health: You, your doctor or new technologies?," CEIS Research Paper 167, Tor Vergata University, CEIS, revised 28 May 2010.

  4. Paul Grootendorst, 2007. "A review of instrumental variables estimation in the applied health sciences," Social and Economic Dimensions of an Aging Population Research Papers 215, McMaster University.

    Cited by:

    1. Daniel Solís & Boris E. Bravo‐Ureta & Ricardo E. Quiroga, 2009. "Technical Efficiency among Peasant Farmers Participating in Natural Resource Management Programmes in Central America," Journal of Agricultural Economics, Wiley Blackwell, vol. 60(1), pages 202-219, February.
    2. Gabriela V. Cohen Freue & Hernan Ortiz-Molina & Ruben H. Zamar, 2013. "A Natural Robustification of the Ordinary Instrumental Variables Estimator," Biometrics, The International Biometric Society, vol. 69(3), pages 641-650, September.

  5. Paul Grootendorst, 2007. "Effects of 'Authorized-Generics' on Canadian Drug Prices," Social and Economic Dimensions of an Aging Population Research Papers 201, McMaster University.

    Cited by:

    1. Ricardo Gonçalves & Vasco Rodrigues & Hélder Vasconcelos, 2015. "Reference pricing in the presence of pseudo-generics," International Journal of Health Economics and Management, Springer, vol. 15(3), pages 281-305, September.

  6. Paul V. Grootendorst & John K. Marshall & Anne M. Holbrook & Lisa R. Dolovich & Bernie J. O'Brien & Adrian R. Levy, 2004. "The Impact of Differential Cost Sharing of Non-Steroidal Anti-Inflammatory Agents on the Use and Costs of Analgesic Drugs," Social and Economic Dimensions of an Aging Population Research Papers 115, McMaster University.

    Cited by:

    1. Tom Stargardt, 2010. "The impact of reference pricing on switching behaviour and healthcare utilisation: the case of statins in Germany," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(3), pages 267-277, June.
    2. Schneeweiss, Sebastian, 2007. "Reference drug programs: Effectiveness and policy implications," Health Policy, Elsevier, vol. 81(1), pages 17-28, April.
    3. Simone Ghislandi & Patrizio Armeni & Claudio Jommi, 2013. "The impact of generic reference pricing in Italy, a decade on," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(6), pages 959-969, December.
    4. Matteo Galizzi & Simone Ghislandi & Marisa Miraldo, 2011. "Effects of Reference Pricing in Pharmaceutical Markets," PharmacoEconomics, Springer, vol. 29(1), pages 17-33, January.
    5. Paul Grootendorst & David Stewart, 2006. "A re-examination of the impact of reference pricing on anti-hypertensive drug plan expenditures in British Columbia," Health Economics, John Wiley & Sons, Ltd., vol. 15(7), pages 735-742.
    6. Hokkanen, Joni & Kangasharju, Aki & Linnosmaa, Ismo & Valtonen, Hannu, 2012. "Generic substitution policy, prices and market structure: evidence from a quasi-experiment in Finland," Working Papers 35, VATT Institute for Economic Research.

  7. Alan, Sule & Crossley, Thomas F. & Grootendorst, Paul & Veall, Michael R., 2003. "Out-of-Pocket Prescription Drug Expenditures and Public Prescription Drug Programs," IZA Discussion Papers 695, Institute of Labor Economics (IZA).

    Cited by:

    1. Mamedov, Arseny (Мамедов, Арсений) & Hudko, E. (Худько, Е.) & Belev, Sergei (Белев, Сергей) & Moguchev, Nikita Sergeevich (Могучев, Никита Сергеевич), 2016. "Comparative Analysis of the Effectiveness of Individual Instruments of State Investment Policy
      [Сравнительный Анализ Эффективности Применения Отдельных Инструментов Государственной Инвестиционной П
      ," Working Papers 3052, Russian Presidential Academy of National Economy and Public Administration.
    2. Vincenzo Atella & Franco Peracchi & Domenico Depalo & Claudio Rossetti, 2006. "Drug compliance, co-payment and health outcomes: evidence from a panel of Italian patients," Health Economics, John Wiley & Sons, Ltd., vol. 15(9), pages 875-892.

  8. Paul V. Grootendorst & Mitchell Levine, 2002. "Do Drug Plans Matter? Effects of Drug Plan Eligibility on Drug Use Among the Elderly, Social Assistance Recipients and the General Population," Social and Economic Dimensions of an Aging Population Research Papers 73, McMaster University.

    Cited by:

    1. Filippini, M. & Masiero, G. & Moschetti, K., 2009. "Regional consumption of antibiotics: A demand system approach," Economic Modelling, Elsevier, vol. 26(6), pages 1389-1397, November.
    2. Thomas F. Crossley & Paul Grootendorst & Sule Korkmaz & Michael R. Veall, 2000. "The Effects of Drug Subsidies on Out-of Pocket Prescription Drug Expenditures by Seniors: Regional Evidence from Canada," Quantitative Studies in Economics and Population Research Reports 350, McMaster University.
    3. Marin C. Gemmill & Joan Costa-Font & Alistair McGuire, 2007. "In search of a corrected prescription drug Elasticity estimate: a meta-regression approach," Health Economics, John Wiley & Sons, Ltd., vol. 16(6), pages 627-643.
    4. Astrid Kiil & Kurt Houlberg, 2014. "How does copayment for health care services affect demand, health and redistribution? A systematic review of the empirical evidence from 1990 to 2011," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(8), pages 813-828, November.
    5. Thomas F. Crossley & Paul V. Grootendorst & Michael R. Veall, 2003. "National Catastrophic Drug Insurance Revisited: Who Would Benefit from Senator Kirby's Recommendations?," Social and Economic Dimensions of an Aging Population Research Papers 105, McMaster University.

  9. Paul V. Grootendorst & Lisa R. Dolovich & Anne M. Holbrook & Adrian R. Levy & Bernie J. O'Brien, 2002. "The Impact of Reference Pricing of Cardiovascular Drugs on Health Care Costs and Health Outcomes: Evidence from British Columbia--Volume I: Summary," Social and Economic Dimensions of an Aging Population Research Papers 70, McMaster University.

    Cited by:

    1. Chiara Bonassi & Laura Magazzini & Fabio Pammolli & Massimo Riccaboni & Nicola Carmine Salerno, 2007. "Il prezzo di riferimento nel quadro regolatorio del mercato farmaceutico," Working Papers CERM 04-2007, Competitività, Regole, Mercati (CERM).
    2. Paul Grootendorst & David Stewart, 2006. "A re-examination of the impact of reference pricing on anti-hypertensive drug plan expenditures in British Columbia," Health Economics, John Wiley & Sons, Ltd., vol. 15(7), pages 735-742.

  10. Donald Willison & Mary Wiktorowicz & Paul Grootendorst & Bernie O'Brien & Mitchell Levine & Raisa Deber & Jeremiah Hurley, 2001. "International Experience With Pharmaceutical Policy: Common Challenges and Lessons for Canada," Centre for Health Economics and Policy Analysis Working Paper Series 2001-08, Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada.

    Cited by:

    1. Wright, Donald J., 2004. "The drug bargaining game: pharmaceutical regulation in Australia," Journal of Health Economics, Elsevier, vol. 23(4), pages 785-813, July.
    2. Holst, Jens, 2008. "Kostenbeteiligung für Patienten - Reformansatz ohne Evidenz! Theoretische Betrachtungen und empirische Befunde aus Industrieländern," Discussion Papers, Research Group Public Health SP I 2008-305, WZB Berlin Social Science Center.

  11. Thomas F. Crossley & Paul Grootendorst & Sule Korkmaz & Michael R. Veall, 2000. "The Effects of Drug Subsidies on Out-of Pocket Prescription Drug Expenditures by Seniors: Regional Evidence from Canada," Social and Economic Dimensions of an Aging Population Research Papers 19, McMaster University.

    Cited by:

    1. William H. Crown & Ernst R. Berndt & Onur Baser & Stan N. Finkelstein & Whitney P. Witt & Jonathan Maguire & Kenan E. Haver, 2004. "Benefit Plan Design and Prescription Drug Utilization Among Asthmatics: Do Patient Copayments Matter?," NBER Chapters,in: Frontiers in Health Policy Research, Volume 7, pages 95-128 National Bureau of Economic Research, Inc.
    2. Burcay Erus & Nazli Aktakke, 2012. "Impact of healthcare reforms on out-of-pocket health expenditures in Turkey for public insurees," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(3), pages 337-346, June.
    3. Sam Caldbick & Xiaojing Wu & Tom Lynch & Naser Al-Khatib & Mustafa Andkhoie & Marwa Farag, 2015. "The financial burden of out of pocket prescription drug expenses in Canada," International Journal of Health Economics and Management, Springer, vol. 15(3), pages 329-338, September.
    4. Magnezi, Racheli & Weiss, Yossi & Cohen, Yossi & Shmueli, Amir, 2007. "Development of a capitation scale for IDF career soldiers in Israel," Health Policy, Elsevier, vol. 80(3), pages 459-464, March.
    5. Burçay Erus, 2010. "Impact of Healthcare Reforms on Out-of-Pocket Health Expenditures in Turkey for Public Insurees," Working Papers 544, Economic Research Forum, revised 09 Jan 2010.
    6. Hai Zhong, 2007. "Equity in Pharmaceutical Utilization in Ontario: A Cross Section and Over Time Analysis," University of Western Ontario, Economic Policy Research Institute Working Papers 20071, University of Western Ontario, Economic Policy Research Institute.
    7. Hirschberg, J.G. & Lye, J.N. & Slottje, D.J., 2008. "Inferential methods for elasticity estimates," Journal of Econometrics, Elsevier, vol. 147(2), pages 299-315, December.
    8. J. G. Hirschberg, J. N. Lye & D. J. Slottje, 2008. "Confidence Intervals for Estimates of Elasticities," Department of Economics - Working Papers Series 1053, The University of Melbourne.
    9. Thomas F. Crossley & Paul V. Grootendorst & Michael R. Veall, 2003. "National Catastrophic Drug Insurance Revisited: Who Would Benefit from Senator Kirby's Recommendations?," Social and Economic Dimensions of an Aging Population Research Papers 105, McMaster University.
    10. Vincenzo Atella & Franco Peracchi & Domenico Depalo & Claudio Rossetti, 2006. "Drug compliance, co-payment and health outcomes: evidence from a panel of Italian patients," Health Economics, John Wiley & Sons, Ltd., vol. 15(9), pages 875-892.

  12. P Grootendorst & D Feeny & W Furlong, 1999. "Health Utilities Index Mark 3: Evidence of Construct Validity for Stroke and Arthritis in a Population Health Survey," Centre for Health Economics and Policy Analysis Working Paper Series 1999-06, Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada.

    Cited by:

    1. Layes, Audrey & Asada, Yukiko & Kephart, George, 2012. "Whiners and deniers – What does self-rated health measure?," Social Science & Medicine, Elsevier, vol. 75(1), pages 1-9.
    2. Eugenio Zucchelli & Andrew M Jones & Nigel Rice, 2012. "The evaluation of health policies through dynamic microsimulation methods," International Journal of Microsimulation, International Microsimulation Association, vol. 5(1), pages 2-20.
    3. Zucchelli, E & Jones, A.M & Rice, N, 2010. "The evaluation of health policies through microsimulation methods," Health, Econometrics and Data Group (HEDG) Working Papers 10/03, HEDG, c/o Department of Economics, University of York.
    4. Peter Franks & Erica I. Lubetkin & Joy Melnikow, 2007. "Do personal and societal preferences differ by socio-demographic group?," Health Economics, John Wiley & Sons, Ltd., vol. 16(3), pages 319-325.
    5. Steven Prus & Zhiqiu Lin, 2005. "Ethnicity and Health: An Analysis of Physical Health Differences across Twenty-one Ethnocultural Groups in Canada," Social and Economic Dimensions of an Aging Population Research Papers 143, McMaster University.
    6. Steven Prus, 2007. "Age, SES, and Health: A Population Level Analysis of Health Inequalities over the Life Course," Social and Economic Dimensions of an Aging Population Research Papers 181, McMaster University.

  13. P Grootendorst, 1999. "Beneficiary Cost Sharing Under Canadian Provincial Prescription Drug Benefit Programs: History and Assessment," Centre for Health Economics and Policy Analysis Working Paper Series 1999-10, Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada.

    Cited by:

    1. Allin, Sara & Law, Michael R. & Laporte, Audrey, 2013. "How does complementary private prescription drug insurance coverage affect seniors’ use of publicly funded medications?," Health Policy, Elsevier, vol. 110(2), pages 147-155.
    2. William H. Crown & Ernst R. Berndt & Onur Baser & Stan N. Finkelstein & Whitney P. Witt & Jonathan Maguire & Kenan E. Haver, 2004. "Benefit Plan Design and Prescription Drug Utilization Among Asthmatics: Do Patient Copayments Matter?," NBER Chapters,in: Frontiers in Health Policy Research, Volume 7, pages 95-128 National Bureau of Economic Research, Inc.
    3. Thomas F. Crossley & Paul Grootendorst & Sule Korkmaz & Michael R. Veall, 2000. "The Effects of Drug Subsidies on Out-of Pocket Prescription Drug Expenditures by Seniors: Regional Evidence from Canada," Quantitative Studies in Economics and Population Research Reports 350, McMaster University.
    4. Sule Alan & Thomas F. Crossley & Paul Grootendorst & Michael R. Veall, 2002. "Out-of-Pocket Prescription Drug Expenditures and Public Prescription Drug Programs," Quantitative Studies in Economics and Population Research Reports 379, McMaster University.
    5. Bhardwaj, Ramesh, 2015. "Restraining High and Rising Cancer Drug Prices: Need for Accelerating R&D Productivity and Aligning Prices with Value," MPRA Paper 63405, University Library of Munich, Germany.
    6. Paul V. Grootendorst & Mitchell Levine, 2002. "Do Drug Plans Matter? Effects of Drug Plan Eligibility on Drug Use Among the Elderly, Social Assistance Recipients and the General Population," Social and Economic Dimensions of an Aging Population Research Papers 73, McMaster University.
    7. Hai Zhong, 2007. "Equity in Pharmaceutical Utilization in Ontario: A Cross Section and Over Time Analysis," University of Western Ontario, Economic Policy Research Institute Working Papers 20071, University of Western Ontario, Economic Policy Research Institute.
    8. Thomas F. Crossley & Paul V. Grootendorst & Michael R. Veall, 2003. "National Catastrophic Drug Insurance Revisited: Who Would Benefit from Senator Kirby's Recommendations?," Social and Economic Dimensions of an Aging Population Research Papers 105, McMaster University.

  14. Paul Grootendorst & David Feeney & W. Furlong, 1999. "Evidence of Construct Validity for Stoke and Arthritis in a Population Health Survey," Department of Economics Working Papers 1999-09, McMaster University.

    Cited by:

    1. Peter Franks & Erica I. Lubetkin & Joy Melnikow, 2007. "Do personal and societal preferences differ by socio-demographic group?," Health Economics, John Wiley & Sons, Ltd., vol. 16(3), pages 319-325.
    2. Steven Prus & Zhiqiu Lin, 2005. "Ethnicity and Health: An Analysis of Physical Health Differences across Twenty-one Ethnocultural Groups in Canada," Social and Economic Dimensions of an Aging Population Research Papers 143, McMaster University.

  15. Donald Willison & Paul Grootendorst & Jeremiah Hurley, 1998. "Variance in Pharmacare Coverage Across Canada," Centre for Health Economics and Policy Analysis Working Paper Series 1998-08, Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada.

    Cited by:

    1. Deborah A. Freund & Don Willison & Grant D. Reeher & Bernie O'Brien & Jarold Cosby & Amy Ferraro, 2000. "Pharmaceuticals and the Elderly: A Comparative Analysis," Center for Policy Research Working Papers 17, Center for Policy Research, Maxwell School, Syracuse University.

  16. Paul Grootendorst & Laurie Goldsmith & Jeremiah Hurley & Bernie O'Brien & Lisa Dolovich, 1996. "Financial Incentives to Dispense Low-Cost Drugs: A Case Study of British Columbia Pharmacare," Centre for Health Economics and Policy Analysis Working Paper Series 1996-08, Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada.

    Cited by:

    1. Morgan, Steven G. & Agnew, Jonathan D. & Barer, Morris L., 2004. "Seniors' prescription drug cost inflation and cost containment: evidence from British Columbia," Health Policy, Elsevier, vol. 68(3), pages 299-307, June.
    2. Ernst R. Berndt & Margaret Kyle & Davina Ling, 2003. "The Long Shadow of Patent Expiration. Generic Entry and Rx-to-OTC Switches," NBER Chapters,in: Scanner Data and Price Indexes, pages 229-274 National Bureau of Economic Research, Inc.

  17. P Grootendorst & B O'Brien & G Anderson, 1995. "On Becoming 65 in Ontario: Effects of Provincial Drug Plan Eligibility on Utilization of Prescription Medicines," Centre for Health Economics and Policy Analysis Working Paper Series 1995-01, Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada.

    Cited by:

    1. Thomas F. Crossley & Paul Grootendorst & Sule Korkmaz & Michael R. Veall, 2000. "The Effects of Drug Subsidies on Out-of Pocket Prescription Drug Expenditures by Seniors: Regional Evidence from Canada," Quantitative Studies in Economics and Population Research Reports 350, McMaster University.

  18. P Grootendorst & D Feeny & W Furlong, 1994. "Does It Matter Whom and How You Ask? Inter and Intra-rater Agreement in the Ontario Health Survey," Centre for Health Economics and Policy Analysis Working Paper Series 1994-12, Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada.

    Cited by:

    1. Paul Contoyannis & Andrew M. Jones & Nigel Rice, 2004. "The dynamics of health in the British Household Panel Survey," Journal of Applied Econometrics, John Wiley & Sons, Ltd., vol. 19(4), pages 473-503.
    2. Bérengère Davin & Xavier Joutard & Alain Paraponaris, 2019. "“If You Were Me”: Proxy Respondents’ Biases in Population Health Surveys," AMSE Working Papers 1905, Aix-Marseille School of Economics, France.
    3. Phipps , Shelley & Curtis, Laurie & Dooley , Martin, 2002. "Qui a raison des parents ou des enfants? Evaluation de l'accord des parents et des enfants dans l'Enquete longitudinale nationale sur les enfants et les jeunes," Direction des études analytiques : documents de recherche 2002181f, Statistics Canada, Direction des études analytiques.
    4. Cristina Hernández-Quevedo & Andrew M Jones & Nigel Rice, 2005. "Reporting bias and heterogeneity in selfassessed health. Evidence from the British Household Panel Survey," Health, Econometrics and Data Group (HEDG) Working Papers 05/04, HEDG, c/o Department of Economics, University of York.
    5. Phipps , Shelley & Curtis, Laurie & Dooley , Martin, 2002. "Does Parent or Child Know Best? an Assessment of Parent/Child Agreement in the Canadian National Longitudinal Survey of Children and Youth," Analytical Studies Branch Research Paper Series 2002181e, Statistics Canada, Analytical Studies Branch.
    6. Bérengère Davin & Xavier Joutard & Alain Paraponaris, 2019. ""If You Were Me": Proxy Respondents' Biases in Population Health Surveys," Working Papers halshs-02036434, HAL.
    7. Crossley, Thomas F. & Kennedy, Steven, 2002. "The reliability of self-assessed health status," Journal of Health Economics, Elsevier, vol. 21(4), pages 643-658, July.
    8. Thomas F. Crossley & Steven Kennedy, 2000. "The Stability of Self Assessed Health Status," Social and Economic Dimensions of an Aging Population Research Papers 26, McMaster University.

  19. Christopher Auld & Paul Grootendorst, "undated". "An Empirical Analysis of Milk Addiction," Working Papers 2001-17, Department of Economics, University of Calgary, revised 05 Dec 2001.

    Cited by:

    1. David Aristei & Luca Pieroni, 2007. "Habits, Complementarities and Heterogenenity in Alcohol and Tobacco Demand: A Multivariate Dynamic Model," Working Papers 38/2007, University of Verona, Department of Economics.
    2. Kan, Kamhon, 2007. "Cigarette smoking and self-control," Journal of Health Economics, Elsevier, vol. 26(1), pages 61-81, January.
    3. Junmin Wan, 2005. "Rational Addiction with Optimal Inventories: Theory and Evidence from Cigarette Purchases in Japan," ISER Discussion Paper 0641, Institute of Social and Economic Research, Osaka University.
    4. Andrew M. Jones, 2007. "Identification of treatment effects in Health Economics," Health Economics, John Wiley & Sons, Ltd., vol. 16(11), pages 1127-1131.
    5. K. Rebecca Scott, 2012. "Rational Habits and Uncertain Prices: Simulating Gasoline Consumption Behavior," Economics Series Working Papers 596, University of Oxford, Department of Economics.
    6. Sophie Massin, 2008. "La notion d'addiction en économie : la théorie du choix rationnel à l'épreuve," Documents de travail du Centre d'Economie de la Sorbonne r08054, Université Panthéon-Sorbonne (Paris 1), Centre d'Economie de la Sorbonne.
    7. Reshmaan Hussam & Atonu Rabbani & Giovanni Reggiani & Natalia Rigol, 2017. "Habit Formation and Rational Addiction: A Field Experiment in Handwashing," Harvard Business School Working Papers 18-030, Harvard Business School.
    8. Pierpaolo Pierani & Silvia Tiezzi, 2005. "Addiction and the Interaction between Alcohol and Tobacco Consumption," Department of Economics University of Siena 470, Department of Economics, University of Siena.
    9. Evgeny Yakovlev, 2012. "Peers and Alcohol: Evidence from Russia," Working Papers w0182, New Economic School (NES).
    10. Audrey Laporte & Adrian Rohit Dass & Brian Ferguson, 2015. "Is the Rational Addiction model inherently impossible to estimate?," Working Papers 150011, Canadian Centre for Health Economics, revised Jun 2016.
    11. Jonathan Caulkins & Gustav Feichtinger & Richard Hartl & Peter Kort & Andreas Novak & Andrea Seidl, 2013. "Multiple equilibria and indifference-threshold points in a rational addiction model," Central European Journal of Operations Research, Springer;Slovak Society for Operations Research;Hungarian Operational Research Society;Czech Society for Operations Research;Österr. Gesellschaft für Operations Research (ÖGOR);Slovenian Society Informatika - Section for Operational Research;Croatian Operational Research Society, vol. 21(3), pages 507-522, September.
    12. Badi H. Baltagi & Ingo Geishecker, 2006. "Rational alcohol addiction: evidence from the Russian longitudinal monitoring survey," Health Economics, John Wiley & Sons, Ltd., vol. 15(9), pages 893-914.
    13. Vining, Aidan & Weimer, David L, 2010. "An Assessment of Important Issues Concerning the Application of Benefit-Cost Analysis to Social Policy," Journal of Benefit-Cost Analysis, Cambridge University Press, vol. 1(01), pages 1-40, July.
    14. Aju Fenn & John Schroeter, 2004. "Cigarettes and addiction information: simulating the demand effects of the tobacco industry's 'conspiracy of silence'," Applied Economics, Taylor & Francis Journals, vol. 36(19), pages 2151-2159.
    15. Scott, K. Rebecca, 2012. "Rational habits in gasoline demand," Energy Economics, Elsevier, vol. 34(5), pages 1713-1723.
    16. Xiaoou Liu & Rigoberto Lopez, 2012. "Evidence of rational addiction to carbonated soft drinks?," China Agricultural Economic Review, Emerald Group Publishing, vol. 4(3), pages 300-317, August.
    17. Evgeny Yakovlev, 2016. "Demand for Alcohol Consumption and Implication for Mortality: Evidence from Russia," Working Papers w0221, Center for Economic and Financial Research (CEFIR).
    18. Junmin Wan, 2004. "Consumption of Cigarettes, Nicotine, and Tar under Anti-smoking Policies: Japan as a Case Study," Discussion Papers in Economics and Business 04-12-Rev, Osaka University, Graduate School of Economics, revised Mar 2006.
    19. Silvia Tiezzi, 2005. "An empirical analysis of tobacco addiction in Italy," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(3), pages 233-243, September.
    20. M. Christopher Auld, 2012. "Using Observational Data to Identify the Causal Effects of Health-related Behaviour," Chapters,in: The Elgar Companion to Health Economics, Second Edition, chapter 4 Edward Elgar Publishing.
    21. Jason M. Fletcher & Partha Deb & Jody L. Sindelar, 2009. "Tobacco Use, Taxation and Self Control in Adolescence," NBER Working Papers 15130, National Bureau of Economic Research, Inc.
    22. Thomas Demuynck & Ewout Verriest, 2013. "I'll never forget my first cigarette: A revealed preference analysis of the 'habits as durables' model," ULB Institutional Repository 2013/252235, ULB -- Universite Libre de Bruxelles.
    23. D. Dragone & D. Raggi, 2018. "Testing Rational Addiction: When Lifetime is Uncertain, One Lag is Enough," Working Papers wp1119, Dipartimento Scienze Economiche, Universita' di Bologna.
    24. Hyeokkoo Eric Kwon & Hyunji So & Sang Pil Han & Wonseok Oh, 2016. "Excessive Dependence on Mobile Social Apps: A Rational Addiction Perspective," Information Systems Research, INFORMS, vol. 27(4), pages 919-939, December.
    25. David L. Weimer & Aidan R. Vining & Randall K. Thomas, 2009. "Cost-benefit analysis involving addictive goods: contingent valuation to estimate willingness-to-pay for smoking cessation," Health Economics, John Wiley & Sons, Ltd., vol. 18(2), pages 181-202.
    26. Filippini, Massimo & Hirl, Bettina & Masiero, Giuliano, 2018. "Habits and rational behaviour in residential electricity demand," Resource and Energy Economics, Elsevier, vol. 52(C), pages 137-152.
    27. Julian Reif, 2019. "A Model Of Addiction And Social Interactions," Economic Inquiry, Western Economic Association International, vol. 57(2), pages 759-773, April.
    28. Junmin Wan, 2004. "Cigarette Tax Revenues and Tobacco Control in Japan," Discussion Papers in Economics and Business 04-11-Rev, Osaka University, Graduate School of Economics, revised Feb 2006.
    29. Badi H. Baltagi & James M. Griffin, 2002. "Rational addiction to alcohol: panel data analysis of liquor consumption," Health Economics, John Wiley & Sons, Ltd., vol. 11(6), pages 485-491.

Articles

  1. Emmanuelle Piérard & Paul Grootendorst, 2014. "Do downturns cause desperation? The effect of economic conditions on suicide rates in Canada," Applied Economics, Taylor & Francis Journals, vol. 46(10), pages 1081-1092, April.

    Cited by:

    1. Carla Blázquez-Fernández & David Cantarero-Prieto & Marta Pascual-Sáez, 2017. "What Does It Drive the Relationship Between Suicides and Economic Conditions? New Evidence from Spain," Social Indicators Research: An International and Interdisciplinary Journal for Quality-of-Life Measurement, Springer, vol. 130(3), pages 1087-1099, February.

  2. Morgan, Steve & Grootendorst, Paul & Lexchin, Joel & Cunningham, Colleen & Greyson, Devon, 2011. "The cost of drug development: A systematic review," Health Policy, Elsevier, vol. 100(1), pages 4-17, April.

    Cited by:

    1. Feng Xie, 2018. "Highly Priced Gene Therapies: A Wake-Up Call for Early Price Regulation," PharmacoEconomics, Springer, vol. 36(8), pages 883-888, August.
    2. Wittmann, Nadine, 2014. "Economic reasoning on the correlation between life expectancy and economic development: Exploring alternative routes," Economics Discussion Papers 2014-43, Kiel Institute for the World Economy (IfW).
    3. G. Kent Fellows & Daniel J. Dutton & Aidan Hollis, 2018. "Making Sure Orphan Drugs Don’t Get Left Behind," SPP Communique, The School of Public Policy, University of Calgary, vol. 10(6), August.
    4. von Bandemer, Stephan & Merkel, Sebastian & Nimako-Doffour, Anna, 2012. "Medizinisch-technische Innovationen in der Gesundheitswirtschaft am Beispiel der Neuen Untersuchungs- und Behandlungsmethoden (NUB)," Forschung Aktuell 04/2012, Institut Arbeit und Technik (IAT), Westfälische Hochschule, University of Applied Sciences.
    5. Vargas-Peláez, Claudia Marcela & Soares, Luciano & Rover, Marina Raijche Mattozo & Blatt, Carine Raquel & Mantel-Teeuwisse, Aukje & Rossi Buenaventura, Francisco Augusto & Restrepo, Luis Guillermo & L, 2017. "Towards a theoretical model on medicines as a health need," Social Science & Medicine, Elsevier, vol. 178(C), pages 167-174.
    6. Charles Baum & Katherine Andino & Eric Wittbrodt & Shelley Stewart & Keith Szymanski & Robin Turpin, 2015. "The Challenges and Opportunities Associated with Reimbursement for Obesity Pharmacotherapy in the USA," PharmacoEconomics, Springer, vol. 33(7), pages 643-653, July.
    7. Hollis, Aidan & Ahmed, Ziana, 2014. "The path of least resistance: Paying for antibiotics in non-human uses," Health Policy, Elsevier, vol. 118(2), pages 264-270.
    8. Makai, Peter & Brouwer, Werner B.F. & Koopmanschap, Marc A. & Stolk, Elly A. & Nieboer, Anna P., 2014. "Quality of life instruments for economic evaluations in health and social care for older people: A systematic review," Social Science & Medicine, Elsevier, vol. 102(C), pages 83-93.
    9. Kisoon Shin & Daeho Lee & Kwangsoo Shin & Eungdo Kim, 2018. "Measuring the Efficiency of U.S. Pharmaceutical Companies Based on Open Innovation Types," Journal of Open Innovation: Technology, Market, and Complexity, MDPI, Open Access Journal, vol. 4(3), pages 1-21, August.
    10. Uwe Kehrel & Kai Klischan & Nathalie Sick, 2016. "Why Research Partnerships Fail in the Biotechnology Sector — An Empirical Analysis of Strategic Partnerships," International Journal of Innovation and Technology Management (IJITM), World Scientific Publishing Co. Pte. Ltd., vol. 13(01), pages 1-23, February.
    11. Chen, Xu & Yang, Huan & Wang, Xiaojun, 2019. "Effects of price cap regulation on the pharmaceutical supply chain," Journal of Business Research, Elsevier, vol. 97(C), pages 281-290.
    12. Anita Chawla & Ginger Carls & Edmund Deng & Edward Tuttle, 2015. "The Expected Net Present Value of Developing Weight Management Drugs in the Context of Drug Safety Litigation," PharmacoEconomics, Springer, vol. 33(7), pages 749-763, July.
    13. Pereira, Cristiano Gonçalves & Lavoie, Joao Ricardo & Garces, Edwin & Basso, Fernanda & Dabić, Marina & Porto, Geciane Silveira & Daim, Tugrul, 2019. "Forecasting of emerging therapeutic monoclonal antibodies patents based on a decision model," Technological Forecasting and Social Change, Elsevier, vol. 139(C), pages 185-199.

  3. Paul Grootendorst & David Stewart, 2006. "A re-examination of the impact of reference pricing on anti-hypertensive drug plan expenditures in British Columbia," Health Economics, John Wiley & Sons, Ltd., vol. 15(7), pages 735-742.

    Cited by:

    1. Tom Stargardt, 2010. "The impact of reference pricing on switching behaviour and healthcare utilisation: the case of statins in Germany," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(3), pages 267-277, June.
    2. Kanavos, Panos G. & Vandoros, Sotiris, 2011. "Determinants of branded prescription medicine prices in OECD countries," Health Economics, Policy and Law, Cambridge University Press, vol. 6(03), pages 337-367, June.
    3. Fiorio, Carlo V. & Siciliani, Luigi, 2010. "Co-payments and the demand for pharmaceuticals: Evidence from Italy," Economic Modelling, Elsevier, vol. 27(4), pages 835-841, July.
    4. Kalo, Zoltan & Muszbek, Noemi & Bodrogi, Jozsef & Bidlo, Judit, 2007. "Does therapeutic reference pricing always result in cost-containment?: The Hungarian evidence," Health Policy, Elsevier, vol. 80(3), pages 402-412, March.
    5. Dominik J. Wettstein & Stefan Boes, 2019. "Effectiveness of National Pricing Policies for Patent-Protected Pharmaceuticals in the OECD: A Systematic Literature Review," Applied Health Economics and Health Policy, Springer, vol. 17(2), pages 143-162, April.
    6. Matteo Galizzi & Simone Ghislandi & Marisa Miraldo, 2011. "Effects of Reference Pricing in Pharmaceutical Markets," PharmacoEconomics, Springer, vol. 29(1), pages 17-33, January.
    7. Hokkanen, Joni & Kangasharju, Aki & Linnosmaa, Ismo & Valtonen, Hannu, 2012. "Generic substitution policy, prices and market structure: evidence from a quasi-experiment in Finland," Working Papers 35, VATT Institute for Economic Research.
    8. Håkonsen, Helle & Horn, Anne Marie & Toverud, Else-Lydia, 2009. "Price control as a strategy for pharmaceutical cost containment--What has been achieved in Norway in the period 1994-2004?," Health Policy, Elsevier, vol. 90(2-3), pages 277-285, May.

  4. Paul Contoyannis & Jeremiah Hurley & Paul Grootendorst & Sung-Hee Jeon & Robyn Tamblyn, 2005. "Estimating the price elasticity of expenditure for prescription drugs in the presence of non-linear price schedules: an illustration from Quebec, Canada," Health Economics, John Wiley & Sons, Ltd., vol. 14(9), pages 909-923.

    Cited by:

    1. Merja Halme & Kari Linden & Kimmo Kääriä, 2009. "Patients’ Preferences for Generic and Branded Over-the-Counter Medicines," The Patient: Patient-Centered Outcomes Research, Springer;Johns Hopkins Bloomberg School of Public Health, vol. 2(4), pages 243-255, December.
    2. Marianne Simonsen & Lars Skipper & Niels Skipper, 2010. "Price Sensitivity of Demand for Prescription Drugs: Exploiting a Regression Kink Design," Economics Working Papers 2010-03, Department of Economics and Business Economics, Aarhus University.
    3. Mwabu, Germano, 2007. "Health Economics for Low-Income Countries," Center Discussion Papers 10118, Yale University, Economic Growth Center.
    4. Dag Morten Dalen & Marilena Locatelli & Enrico Sorisio & Steinar Strøm, 2011. "A Probability Approach to Pharmaceutical Demand and Price Setting: Does the Identity of the Third-Party Payer Matters for Prescribing Doctors?," CESifo Working Paper Series 3643, CESifo Group Munich.
    5. Hugo Vilares & Manuel Coutinho Pereira, 2014. "A review of the pharmaceutical market in Portugal," Economic Bulletin and Financial Stability Report Articles and Banco de Portugal Economic Studies, Banco de Portugal, Economics and Research Department.
    6. Laura Guadalupe González Ortiz & Giuliano Masiero, 2011. "Disentangling spillover effects of antibiotic consumption: a spatial panel approach," Working Papers 1104, Department of Economics and Technology Management, University of Bergamo.
    7. Wang, Chao & Li, Qing & Sweetman, Arthur & Hurley, Jeremiah, 2015. "Mandatory universal drug plan, access to health care and health: Evidence from Canada," Journal of Health Economics, Elsevier, vol. 44(C), pages 80-96.
    8. Fiorio, Carlo V. & Siciliani, Luigi, 2010. "Co-payments and the demand for pharmaceuticals: Evidence from Italy," Economic Modelling, Elsevier, vol. 27(4), pages 835-841, July.
    9. Skipper, Niels, 2012. "On reimbursement reforms and stockpiling of prescription drugs: The case of insulin," Health Policy, Elsevier, vol. 106(3), pages 233-240.
    10. Chad D. Meyerhoefer & Samuel H. Zuvekas, 2010. "New estimates of the demand for physical and mental health treatment," Health Economics, John Wiley & Sons, Ltd., vol. 19(3), pages 297-315.
    11. Sergei Koulayev & Niels Skipper & Emilia Simeonova, 2013. "Who Is in Control? The Determinants of Patient Adherence with Medication Therapy," NBER Working Papers 19496, National Bureau of Economic Research, Inc.
    12. Kurt R. Brekke & Astrid L. Grasdal & Tor Helge Holmås, 2007. "Regulation and Pricing of Pharmaceuticals: Reference Pricing or Price Cap Regulation?," CESifo Working Paper Series 2059, CESifo Group Munich.
    13. Paul Grootendorst, 2012. "Prescription Drug Insurance and Reimbursement," Chapters,in: The Elgar Companion to Health Economics, Second Edition, chapter 11 Edward Elgar Publishing.
    14. Kai Yeung & Anirban Basu & Ryan N. Hansen & Sean D. Sullivan, 2016. "Price Elasticities of Pharmaceuticals in a Value-Based-Formulary Setting," NBER Working Papers 22308, National Bureau of Economic Research, Inc.
    15. Kurt Brekke & Dag Dalen & Tor Holmås, 2014. "Diffusion of pharmaceuticals: cross-country evidence of anti-TNF drugs," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(9), pages 937-951, December.
    16. Farbmacher, Helmut & Ihle, Peter & Schubert, Ingrid & Winter, Joachim & Wuppermann, Amelie, 2017. "Heterogeneous Effects of a Nonlinear Price Schedule for Outpatient Care," Munich Reprints in Economics 49875, University of Munich, Department of Economics.
    17. Niels Skipper, 2010. "On Utilization and Stockpiling of Prescription Drugs when Co-payments Increase: Heterogeneity across Types of Drugs," Economics Working Papers 2010-12, Department of Economics and Business Economics, Aarhus University.
    18. Astrid Kiil & Kurt Houlberg, 2014. "How does copayment for health care services affect demand, health and redistribution? A systematic review of the empirical evidence from 1990 to 2011," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(8), pages 813-828, November.
    19. Dalen, Dag Morten & Sorisio, Enrico & Strøm, Steinar, 2009. "Choosing among Competing Blockbusters: Does the Identity of the Third-party Payer Matter for Prescribing Doctors?," Memorandum 10/2009, Oslo University, Department of Economics.
    20. Li, Xin & Guh, Daphne & Lacaille, Diane & Esdaile, John & Anis, Aslam H., 2007. "The impact of cost sharing of prescription drug expenditures on health care utilization by the elderly: Own- and cross-price elasticities," Health Policy, Elsevier, vol. 82(3), pages 340-347, August.
    21. Dillender, Marcus, 2018. "What happens when the insurer can say no? Assessing prior authorization as a tool to prevent high-risk prescriptions and to lower costs," Journal of Public Economics, Elsevier, vol. 165(C), pages 170-200.

  5. Sule Alan & Thomas Crossley & Paul Grootendorst & Michael Veall, 2005. "Distributional effects of `general population' prescription drug programs in Canada," Canadian Journal of Economics, Canadian Economics Association, vol. 38(1), pages 128-148, February.

    Cited by:

    1. Mark Stabile & Sarah Thomson, 2014. "The Changing Role of Government in Financing Health Care: An International Perspective," Journal of Economic Literature, American Economic Association, vol. 52(2), pages 480-518, June.
    2. Wang, Chao & Li, Qing & Sweetman, Arthur & Hurley, Jeremiah, 2015. "Mandatory universal drug plan, access to health care and health: Evidence from Canada," Journal of Health Economics, Elsevier, vol. 44(C), pages 80-96.
    3. Paul Grootendorst, 2012. "Prescription Drug Insurance and Reimbursement," Chapters,in: The Elgar Companion to Health Economics, Second Edition, chapter 11 Edward Elgar Publishing.
    4. Sam Caldbick & Xiaojing Wu & Tom Lynch & Naser Al-Khatib & Mustafa Andkhoie & Marwa Farag, 2015. "The financial burden of out of pocket prescription drug expenses in Canada," International Journal of Health Economics and Management, Springer, vol. 15(3), pages 329-338, September.
    5. Hai Zhong, 2007. "Equity in Pharmaceutical Utilization in Ontario: A Cross Section and Over Time Analysis," University of Western Ontario, Economic Policy Research Institute Working Papers 20071, University of Western Ontario, Economic Policy Research Institute.
    6. Goldman, Matt & Kaplan, David M., 2017. "Fractional order statistic approximation for nonparametric conditional quantile inference," Journal of Econometrics, Elsevier, vol. 196(2), pages 331-346.

  6. Auld, M. Christopher & Grootendorst, Paul, 2004. "An empirical analysis of milk addiction," Journal of Health Economics, Elsevier, vol. 23(6), pages 1117-1133, November.
    See citations under working paper version above.
  7. Alan, Sule & Crossley, Thomas F. & Grootendorst, Paul & Veall, Michael R., 2002. "The effects of drug subsidies on out-of-pocket prescription drug expenditures by seniors: regional evidence from Canada," Journal of Health Economics, Elsevier, vol. 21(5), pages 805-826, September.
    See citations under working paper version above.
  8. Schneeweiss, Sebastian & Maclure, Malcolm & Walker, Alexander M. & Grootendorst, Paul & Soumerai, Stephen B., 2001. "On the evaluation of drug benefits policy changes with longitudinal claims data: the policy maker's versus the clinician's perspective," Health Policy, Elsevier, vol. 55(2), pages 97-109, February.

    Cited by:

    1. Tom Stargardt, 2010. "The impact of reference pricing on switching behaviour and healthcare utilisation: the case of statins in Germany," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(3), pages 267-277, June.
    2. Stargardt, Tom & Schreyögg, Jonas, 2012. "A framework to evaluate the effects of small area variations in healthcare infrastructure on diagnostics and patient outcomes of rare diseases based on administrative data," Health Policy, Elsevier, vol. 105(2), pages 110-118.

  9. Paul V. Grootendorst, 1997. "Health care policy evaluation using longitudinal insurance claims data: An application of the Panel Tobit estimator," Health Economics, John Wiley & Sons, Ltd., vol. 6(4), pages 365-382.

    Cited by:

    1. Sujin Kim & Soonman Kwon, 2014. "The effect of extension of benefit coverage for cancer patients on health care utilization across different income groups in South Korea," International Journal of Health Economics and Management, Springer, vol. 14(2), pages 161-177, June.
    2. Rettenmaier, Andrew J. & Wang, Zijun, 2006. "Persistence in Medicare reimbursements and personal medical accounts," Journal of Health Economics, Elsevier, vol. 25(1), pages 39-57, January.
    3. Thomas F. Crossley & Paul Grootendorst & Sule Korkmaz & Michael R. Veall, 2000. "The Effects of Drug Subsidies on Out-of Pocket Prescription Drug Expenditures by Seniors: Regional Evidence from Canada," Quantitative Studies in Economics and Population Research Reports 350, McMaster University.
    4. Puenpatom, R. Amy & Rosenman, Robert, 2006. "Efficiency of Thai Provincial Public Hospitals after the Introduction of National Health Insurance Program," Working Papers 12960, Washington State University, School of Economic Sciences.
    5. Falk, Martin & Seim, Katja, 1999. "The impact of information technology on high-skilled labour in services: evidence from firm level panel data," ZEW Discussion Papers 99-58, ZEW - Leibniz Centre for European Economic Research.
    6. Kim, Sujin & Kwon, Soonman, 2014. "Has the National Health Insurance improved the inequality in the use of tertiary-care hospitals in Korea?," Health Policy, Elsevier, vol. 118(3), pages 377-385.
    7. Jeonghoon Ahn, 2004. "Panel Data Sample Selection Model: an Application to Employee Choice of Health Plan Type and Medical Cost Estimation," Econometric Society 2004 Far Eastern Meetings 560, Econometric Society.
    8. Chattopadhyay, Sajal K. & Ebrahim, Shahul H. & Tao, Guoyu & McKenna, Matthew T., 2005. "Use of cervical cancer screening among insured women: the extent of missed opportunities," Health Policy, Elsevier, vol. 73(2), pages 194-201, August.
    9. Jaume Puig-Junoy & Pilar Garcia-Gomez & David Casado-Marin, 2011. "Free Medicines thanks to Retirement: Moral Hazard and Hospitalization Offsets in an NHS," Tinbergen Institute Discussion Papers 11-108/3, Tinbergen Institute.

Chapters

  1. Paul Grootendorst, 2012. "Prescription Drug Insurance and Reimbursement," Chapters,in: The Elgar Companion to Health Economics, Second Edition, chapter 11 Edward Elgar Publishing.

    Cited by:

    1. Birg, Laura, 2013. "Pharmaceutical regulation and health policy objectives," Center for European, Governance and Economic Development Research Discussion Papers 183, University of Goettingen, Department of Economics.

More information

Research fields, statistics, top rankings, if available.

Statistics

Access and download statistics for all items

Co-authorship network on CollEc

NEP Fields

NEP is an announcement service for new working papers, with a weekly report in each of many fields. This author has had 15 papers announced in NEP. These are the fields, ordered by number of announcements, along with their dates. If the author is listed in the directory of specialists for this field, a link is also provided.
  1. NEP-HEA: Health Economics (11) 2000-10-23 2002-11-18 2002-11-18 2002-11-18 2003-01-12 2003-02-10 2003-08-24 2004-12-12 2007-10-06 2012-01-10 2015-05-09. Author is listed
  2. NEP-COM: Industrial Competition (3) 2003-01-12 2007-08-27 2015-05-09
  3. NEP-IPR: Intellectual Property Rights (3) 2009-05-23 2009-08-08 2015-05-09
  4. NEP-INO: Innovation (2) 2009-05-23 2009-08-08
  5. NEP-AGR: Agricultural Economics (1) 2012-01-10
  6. NEP-ECM: Econometrics (1) 2007-08-27
  7. NEP-KNM: Knowledge Management & Knowledge Economy (1) 2009-05-23
  8. NEP-LAW: Law & Economics (1) 2015-05-09
  9. NEP-MIC: Microeconomics (1) 2009-05-23
  10. NEP-PKE: Post Keynesian Economics (1) 2003-02-10

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. For general information on how to correct material on RePEc, see these instructions.

To update listings or check citations waiting for approval, Paul Vincent Grootendorst should log into the RePEc Author Service.

To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.

To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.

Please note that most corrections can take a couple of weeks to filter through the various RePEc services.

IDEAS is a RePEc service hosted by the Research Division of the Federal Reserve Bank of St. Louis . RePEc uses bibliographic data supplied by the respective publishers.